Email
Print
Postmenopausal Vaginal Atrophy Treatment & Drug Market - By Therapy Type (Estrogen-based Drugs & Non-estrogen-based Drugs), By Drug Form (Vaginal Gels, Creams, Tablets, Rings & Patches), By Geography - Global Opportunity Analysis & Industry Forecast, 2023-2030
Postmenopausal Vaginal Atrophy Treatment & Drug Market Overview
The Postmenopausal Vaginal Atrophy Treatment & Drug Market size is estimated to reach $4 billion by 2030, growing at a CAGR of 7.3% during the forecast period 2023-2030. The increasing number of postmenopausal vaginal therapy medications including estrogen-based drugs delivered through retail pharmacies is set to drive the Postmenopausal Vaginal Atrophy Treatment & Drug Market. The soaring awareness regarding postmenopausal vaginal atrophy is set to propel the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Industry during the forecast period. Vaginal atrophy (atrophic vaginitis) observed in women is thinning, drying and inflammation of vaginal walls that can happen when the body has diminished estrogen. Present treatment alternatives for postmenopausal vaginal atrophy may involve estrogen-based drugs and non-estrogen-based drugs. Based on Drug Form, the Postmenopausal Vaginal Atrophy Treatment & Drug Market is segmented into Vaginal Gels, Creams, Tablets, Rings and Patches. This represents the Postmenopausal Vaginal Atrophy Treatment & Drug Industry Outlook.
Postmenopausal Vaginal Atrophy Treatment & Drug Market Report Coverage
The “Postmenopausal Vaginal Atrophy Treatment & Drug Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Postmenopausal Vaginal Atrophy Treatment & Drug Industry.
| Attribute | Segment |
|---|---|
By Therapy Type |
|
By Drug Form |
|
By Geography |
|
Key Takeaways
- Geographically, North America (Postmenopausal Vaginal Atrophy Treatment & Drug market share) accounted for the highest revenue share in 2022 and is poised to dominate the market over 2023-2030. The growth is driven by the expanding readiness to freely discuss the occurrence and symptoms of postmenopausal vaginal atrophy requiring estrogen-based drugs in the North American region.
- The growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market is being driven by increasing inclination towards non-estrogen-based drugs from systemic estrogen treatments like vaginal gels, creams and patches. However, reduced diagnosis rates and patent expiry of branded products are some of the major factors hampering the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market.
- The Postmenopausal Vaginal Atrophy Treatment & Drug Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Postmenopausal Vaginal Atrophy Treatment & Drug Market report.
Postmenopausal Vaginal Atrophy Treatment & Drug Market Segment Analysis – by Therapy Type
The Postmenopausal Vaginal Atrophy Treatment & Drug Market based on therapy type can be further segmented into Estrogen-based Drugs and Non-estrogen-based Drugs. The Estrogen-based Drugs segment held the largest share of the Postmenopausal Vaginal Atrophy Treatment & Drug market in 2022. This growth is owing to the surging application of estrogen-based drugs for the treatment of postmenopausal vaginal atrophy among women. Systemic estrogen treatments include vaginal gels, creams and patches. The extensive application of topical estrogen therapy in the management of postmenopausal vaginal atrophy is further propelling the growth of the Estrogen-based Drugs segment. Furthermore, the Non-estrogen-based Drugs segment is estimated to grow at the fastest CAGR of 8.3% during the forecast period 2023-2030 due to the emerging application of Non-estrogen-based Drugs for the treatment of menopausal symptoms like hot flushes, symptoms of urogenital atrophy and more.
Postmenopausal
Vaginal Atrophy Treatment & Drug Market Segment Analysis - by Drug Form
The Postmenopausal Vaginal Atrophy Treatment & Drug Market based on drug form can be further segmented into Vaginal Gels, Creams, Tablets, Rings and Patches. The Vaginal Tablets Segment held the largest share of the Postmenopausal Vaginal Atrophy Treatment & Drug market in 2022. This growth is driven by the emerging application of vaginal tablets for the treatment of postmenopausal vaginal atrophy among women. There is greater compliance with vaginal tablets than creams among postmenopausal women. The increasing inclination of postmenopausal women towards vaginal tablets coupled with the increasing prescription of vaginal tablets by physicians is further propelling the growth of this segment. Furthermore, the Creams segment is estimated to grow at the fastest CAGR of 8.5% during the forecast period 2023-2030 due to the extensive application of vaginal creams to treat postmenopausal vaginal atrophy among women.
Postmenopausal Vaginal Atrophy Treatment & Drug Market Segment Analysis - by Geography
The Postmenopausal Vaginal Atrophy Treatment & Drug Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Postmenopausal Vaginal Atrophy Treatment & Drug Market) dominated the Postmenopausal Vaginal Atrophy Treatment & Drug market with a 40% share of the overall market in 2022. The growth of this region is owing to the increasing predominance of postmenopausal vaginal atrophy in the North American region. The growing initiatives by pharmaceutical organizations to produce new formulations are further propelling the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Industry, thereby contributing to the Postmenopausal Vaginal Atrophy Treatment & Drug Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2030. This growth is owing to factors like the increasing predominance of vaginal infection among women in the Asia-Pacific region. The growing initiatives by pharmaceutical organizations to spread awareness are further fueling the progress of the Postmenopausal Vaginal Atrophy Treatment & Drug Market in the Asia-Pacific region.
Postmenopausal Vaginal Atrophy Treatment & Drug Market Drivers
Increasing Investigations Pertaining to Estrogen-based Drugs Like Vaginal Estrogen Creams:
Investigations have been conducted to assess the impact of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women. Fifty menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were chosen and treated with 0.5g vaginal estrogen cream, twice a week for 12 weeks. It has been concluded that vaginal estrogen creams bring about symptomatic alleviation in women of menopausal age in India enduring vaginal atrophy. The increasing investigations pertaining to estrogen-based drugs like vaginal estrogen creams are therefore fueling the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market during the forecast period 2023-2030.
Soaring Utilization of Vaginal Tablets:
Postmenopausal estrogen deficiency may result in symptoms of urogenital atrophy. The establishment of the ultra-low-dose 10-µg estradiol vaginal tablets is conforming with the needs of regulatory agencies and women's health societies regarding the application of the least efficient hormonal dose. Due to its efficiency and safety profiles, in addition to its minimal systemic absorption, the 10-µg estradiol vaginal tablet may provide better reassurance to healthcare providers and postmenopausal women with an annual estradiol administration of only 1.14 mg. The soaring utilization of vaginal tablets is propelling the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Industry, thereby contributing to the Postmenopausal Vaginal Atrophy Treatment & Drug Industry Outlook during the forecast period 2023-2030.
Postmenopausal Vaginal Atrophy Treatment & Drug Market Challenges
Side-effects of Vaginal Gels:
Metronidazole Vaginal Gel is the intravaginal dosage form of the synthetic antibacterial agent, metronidazole, USP at a concentration of 0.75%. Every applicator full of 5 grams of vaginal gel includes nearly 37.5 mg of metronidazole. Vaginal gels like Metrogel – Vaginal Gel with Applicator have certain side effects. Metrogel – vaginal gel with applicator can bring about side effects like stomach discomfort, headache or dizziness. Vaginal discomfort/itching/discharge may happen or worsen. These symptoms may happen due to a new vaginal infection like yeast/fungal infection. In case of symptoms of a severe allergic reaction involving serious dizziness, medical assistance is required without delay. These issues are thus hampering the growth of the Postmenopausal Vaginal Atrophy Treatment & Drug Market.
Key Market Players
Product launches, establishment of more novel applications, product & treatment extensions and R&D activities are key strategies adopted by players in the Postmenopausal Vaginal Atrophy Treatment & Drug Market. The top 10 companies in the Postmenopausal Vaginal Atrophy Treatment & Drug market are:
- EndoCeutics
- Upsher-Smith Laboratories
- TherapeuticsMD
- Bionovo
- Pfizer Inc.
- Novo Nordisk A/S
- Allergan plc
- Shionogi & Co., Ltd.
- Ligand Pharmaceuticals Incorporated
- Bayer AG
Scope of the Report:
| Report Metric | Details |
|---|---|
Base Year Considered | 2022 |
Forecast Period | 2023–2030 |
CAGR | 7.3% |
Market Size by 2030 | $4 billion |
Segments Covered | By Therapy Type, By Drug Form and By Region |
Geographies Covered |
|
Key Market Players |
|
Frequently Asked Questions:
1. What is the growth rate of the Postmenopausal Vaginal
Atrophy Treatment & Drug Market during the forecast period?
The Postmenopausal Vaginal Atrophy Treatment & Drug
Market is estimated to grow at a CAGR of 4.3% during the forecast period
2023-2030.
2. Which region holds the largest market share in the
Postmenopausal Vaginal Atrophy Treatment & Drug Market during the forecast
period 2023-2030?
North America dominated the Postmenopausal Vaginal Atrophy
Treatment & Drug market with a 40% share of the overall market in 2022. The
growth of this region is owing to the increasing predominance of postmenopausal
vaginal atrophy in the region.
3. Which are the leading market players in the
Postmenopausal Vaginal Atrophy Treatment & Drug Market?
EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD,
Bionovo and Pfizer Inc., are some of the leading players in the Postmenopausal
Vaginal Atrophy Treatment & Drug Market.
4. What are the major Postmenopausal Vaginal Atrophy
Treatment & Drug Market trends that would shape the future market?
Some of the key market trends of the Postmenopausal Vaginal
Atrophy Treatment & Drug Market include Growing Healthcare Plans, a Surge
in Demand for Retail Pharmacies, Increased Awareness of the Disease, Increasing
Inclination Towards Non-Estrogen-Based Drugs, and others.
5. What are the driving factors and opportunities in the
Postmenopausal Vaginal Atrophy Treatment & Drug Market?
The key drivers of the market include Increasing
Investigations Pertaining to Estrogen-based Drugs Like Vaginal Estrogen Creams
and Soaring Utilization of Vaginal Tablets. The advent of novel drugs with
improved safety are expected to tap the unmet needs and offer lucrative market
growth opportunities.
Recent Developments
- In January 2022, Novo Nordisk India introduced a first-of-its-kind diabetes treatment medicine in the nation. The firm pronounced that it has launched the world's earliest and only oral semaglutide. This is the first time that the medicine has been developed in an oral form.
- In April 2021, Pfizer Inc. declared that it has acquired Amplyx Pharmaceuticals, Inc. Amplyx’s lead compound is Fosmanogepix (APX001). Fosmanogepix (APX001) is a novel investigational resource under development for the treatment of invasive fungal infections.
- In February 2020, Upsher-Smith Laboratories, LLC declared that it extended its generic portfolio with the introduction of three novel products. The products were Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP and Clonidine Hydrochloride Extended-release Tablets. The firm has dedicated itself to contentiously increasing the count of generic programs in its portfolio.
Relevant Reports:
Report Code: HCR 0302
Report Code: HCR 0304
Report Code: HCR 0051
For more Lifesciences and Healthcare Market reports, please click here